Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > BUSINESS
BUSINESS
- Ribomic Goes Public, Aims to Swing to Black on Aptamers
September 26, 2014
- NBI Paid 14.6 Billion Yen to Healthcare Professionals in 2013
September 26, 2014
- Takeda to Invest 2.5 Billion Yen in US Firm for New Drug Development
September 26, 2014
- OncoTherapy Science Appoints Masaharu Mori, Formerly of Shionogi and Novartis Pharma, as New President
September 26, 2014
- Eisai Sets Up Director Position for Pariet
September 26, 2014
- US FDA Accepts NDA for Abilify Successor Brexpiprazole: Otsuka, Lundbeck
September 26, 2014
- AZ Managed to Speed Up Pilot R&D Projects under New Structure: President
September 25, 2014
- MSD Paid 19.4 Billion Yen to Healthcare Professionals in 2013
September 25, 2014
- Gilead Sciences Submits NDA for Ledipasvir/Sofosbuvir Combination for Genotype 1 Chronic Hepatitis C
September 25, 2014
- AnGes MG to Start Collategene Administration in PIII Study in US as Early as October
September 25, 2014
- Ibandronate Oral Agent to Be Filed for Japan Approval in 2015: Chugai, Taisho
September 24, 2014
- Meiji Seika Pharma Seeks New Indication for Laserphyrin
September 24, 2014
- Mediceo Sets to Increase Qualified Reps to 2,000, Enter Contract PMS Biz within 3 Years
September 22, 2014
- Bristol-Myers Submits NDA for Malignant Melanoma Drug Ipilimumab
September 22, 2014
- Additional Indication Approved for MTPC’s Telavic
September 22, 2014
- RaQualia Wins Use-Patent Allowance for EP4 Antagonist in US
September 22, 2014
- Bayer’s Japan Open Innovation Center Now Up and Running
September 22, 2014
- Sadao Furuichi to Double as Heads of Kracie Pharma, Kracie Pharmaceutical
September 22, 2014
- Huya Bioscience International Opens Tokyo Office
September 19, 2014
- MTPC Generic Arm Seeks to Quickly Broaden Product Lineup, New Alliance a Possibility: Pres.
September 18, 2014
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…